Cocrystal Pharma Inc.

0.4247-0.0002-0.05%Vol 227.85K1Y Perf -59.92%
Aug 11th, 2022 15:59 DELAYED
BID0.4100 ASK0.4247
Open0.4213 Previous Close0.4249
Pre-Market- After-Market0.42
 - -  - -%
Target Price
4.08 
Analyst Rating
Strong Buy 1.00
Potential %
860.68 
Finscreener Ranking
★★★★★     61.19
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★★     57.35
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★★★     59.11
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
8.49 
Earnings Rating
Buy
Market Cap41.40M 
Earnings Date
15th Aug 2022
Alpha0.00 Standard Deviation0.37
Beta0.76 

Today's Price Range

0.40700.4300

52W Range

0.35001.23

5 Year PE Ratio Range

-50.30-2.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
4.86%
1 Month
4.84%
3 Months
10.69%
6 Months
-23.46%
1 Year
-59.92%
3 Years
-83.47%
5 Years
-92.54%
10 Years
-99.19%

TickerPriceChg.Chg.%
COCP0.4247-0.0002-0.05
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
ValuationValueIndustryS&P 500US Markets
-2.70
0.57
132.06
54.20
-3.40
-0.16
0.77
0.75
-12 166 400.00
Forward PE-2.24
PEG-
Financial StrengthValueIndustryS&P 500US Markets
35.20
35.60
0.00
0.01
-3 912.80
Leverage Ratio 1.00
 
ProfitabilityValueIndustryS&P 500US Markets
-
-2 350.40
-2 276.70
-
-5.26
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.04-0.040.00
Q04 2021-0.04-0.040.00
Q03 2021-0.04-0.040.00
Q02 2021-0.04-0.040.00
Q01 2021-0.04-0.040.00
Q04 2020--0.01-
Q03 2020-0.05-0.050.00
Q02 2020-0.04-0.07-75.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.040.00-
9/2022 QR-0.040.00-
12/2022 FY-0.17-13.33Negative
12/2023 FY-0.18-20.00Negative
Next Report Date15th Aug 2022
Estimated EPS Next Report-0.04
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume227.85K
Shares Outstanding97.47K
Shares Float92.83M
Trades Count630
Dollar Volume96.23K
Avg. Volume175.44K
Avg. Weekly Volume197.82K
Avg. Monthly Volume148.89K
Avg. Quarterly Volume179.61K

Cocrystal Pharma Inc. (NASDAQ: COCP) stock closed at 0.4247 per share at the end of the most recent trading day (a -0.05% change compared to the prior day closing price) with a volume of 227.85K shares and market capitalization of 41.40M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Cocrystal Pharma Inc. CEO is Gary L. Wilcox.

The one-year performance of Cocrystal Pharma Inc. stock is -59.92%, while year-to-date (YTD) performance is -34.66%. COCP stock has a five-year performance of -92.54%. Its 52-week range is between 0.35 and 1.23, which gives COCP stock a 52-week price range ratio of 8.49%

Cocrystal Pharma Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 0.57, a price-to-sale (PS) ratio of 132.06, a price to cashflow ratio of 54.20, a PEG ratio of 2.32, a ROA of -24.81%, a ROC of -24.71% and a ROE of -25.51%. The company’s profit margin is -5.26%, its EBITDA margin is -2 276.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cocrystal Pharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. Cocrystal Pharma Inc.’s next earnings report date is 15th Aug 2022.

The consensus rating of Wall Street analysts for Cocrystal Pharma Inc. is Strong Buy (1), with a target price of $4.08, which is +860.68% compared to the current price. The earnings rating for Cocrystal Pharma Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cocrystal Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cocrystal Pharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.56, ATR14 : 0.03, CCI20 : 38.25, Chaikin Money Flow : -0.04, MACD : 0.00, Money Flow Index : 55.00, ROC : 1.17, RSI : 40.63, STOCH (14,3) : 88.12, STOCH RSI : 1.00, UO : 56.48, Williams %R : -11.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cocrystal Pharma Inc. in the last 12-months were: Richard C. Pfenniger (Buy at a value of $41 120)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

CEO: Gary L. Wilcox

Telephone: +1 786 459-1831

Address: 19805 North Creek Parkway, Bothell 98011, WA, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

53%47%

Bearish Bullish

57%43%

Bearish Bullish

53%47%


News

Stocktwits